Corcept Therapeutics (CORT) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Corcept Therapeutics Announces First Quarter 2015 Results and Provides Corporate Update
May 7, 2015 4:06 PM EDTMENLO PARK, CA -- (Marketwired) -- 05/07/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT)
Per-share net loss in first quarter narrows to $0.05, from $0.14 in the same period last year First quarter revenue is $10.1 million, compared to $4.4 million in the first quarter 2014, a 129 percent increase $17.2 million generated from exercise of warrants Patient dosing underway in efficacy portion of Phase 1/2 trial of Korlym to treat triple-negative breast cancer (TNBC); results expected by the end of 2015 Next-generation selective GR antagonist CORT125134 is well-tolerated and functionally active in Phase 1 and is expected to enter Phase 2 in... More